𝔖 Bobbio Scriptorium

✦ LIBER ✦

[Cancer Drug Discovery and Development] The Oncogenomics Handbook Volume 185 || Development and Evaluation of Cancer Therapeutic Agents Targeting TRAIL Receptor 1 and 2

✍ Scribed by LaRochelle, William J.; Shimkets, Richard A.

Book ID: 115445346
Publisher: Humana Press
Year: 2005
Weight: 434 KB
Category: Article
ISBN: 1588294250
DOI: 10.1385/1-59259-893-5:659

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

OP 93 The co-development of a folate rec

OP 93 The co-development of a folate receptor molecular diagnostic imaging agent (99mTc-EC20) and folate receptor targeted drug conjugate (EC145) in the treatment of ovarian cancer patients

✍ S. Ghamande; L. Gilbert; R. Penson; E. Palmer; J. Scott; J. Symanowski; R. Messm 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB

[Heat Shock Proteins] Heat Shock Protein

[Heat Shock Proteins] Heat Shock Proteins in Cancer Volume 2 || Anti-apoptotic, Tumorigenic and Metastatic Potential of Hsp27 (HspB1) and αB-crystallin (HspB5): Emerging Targets for the Development of New Anti-Cancer Therapeutic Strategies

✍ Calderwood, Stuart K.; Sherman, Michael Y.; Ciocca, Daniel R. 📂 Article 📅 2007 🏛 Springer Netherlands ⚖ 323 KB

[ACS Symposium Series] Galectins and Dis

[ACS Symposium Series] Galectins and Disease Implications for Targeted Therapeutics Volume 1115 || Translational Rational for the Clinical Development of OTX-008: A Novel Drug That Inhibits Galectin-1 Expression in Human Cancer Models

✍ Klyosov, Anatole A.; Traber, Peter G. 📂 Article 📅 2012 🏛 American Chemical Society ⚖ 244 KB

[RSC Drug Discovery] New Therapeutic Str

[RSC Drug Discovery] New Therapeutic Strategies for Type 2 Diabetes Volume 74 || Chapter 6. Recent Advances in PTP1B Inhibitor Development for the Treatment of Type 2 Diabetes and Obesity

✍ Jones, Rob M 📂 Article 📅 2012 🏛 Royal Society of Chemistry ⚖ 901 KB

[RSC Drug Discovery] New Therapeutic Str

[RSC Drug Discovery] New Therapeutic Strategies for Type 2 Diabetes Volume 74 || Chapter 11. The Discovery and Development of MB07803, a Second-Generation Fructose-1,6-bisphosphatase Inhibitor with Improved Pharmacokinetic Properties, as a Potential Treatment of Type 2 Diabetes

✍ Jones, Rob M 📂 Article 📅 2012 🏛 Royal Society of Chemistry ⚖ 720 KB